stockrow
Saturday 7 November 2026
Export KAPA’s income statement to Excel — free account
Kairos Pharma, Ltd.
KAPA Healthcare Biotechnology
- EPS
- +25.0%
- Free cash flow
- −25.7%
Quarter to June 2026, against a year earlier
0.49
0.04
+8.89%
Follow KAPA
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Gross margin, % | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| EBT | — | — | — | — | — | — | (1) | (2) | (3) | (5) | (6) | +73.1% | ||||||
| EBT margin, % | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | — | — | — | — | — | — | (1) | (2) | (3) | (5) | (6) | +73.1% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | — | — | — | — | — | — | (0.68) | (1.22) | (1.61) | (2.10) | (1.96) | +45.8% | ||||||
| Cash flow | — | — | — | — | — | — | (0.23) | 0.05 | (2.44) | (1.31) | (1.30) | +79.0% | ||||||
| Capex | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | ||||||
| Free cash flow | — | — | — | — | — | — | (0.23) | 0.05 | (2.44) | (1.31) | (1.30) | +79.0% | ||||||
| Book value | — | — | — | — | — | — | (0.76) | (1.40) | 2.94 | 2.41 | 1.37 | n/m | ||||||
| Shares, m | — | — | — | — | — | — | 2 | 1 | 2 | 3 | 3 | +19.3% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | 0 | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | 0 | 0 | (4) | (3) | (4) | +113.6% | |||||
| Capex | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Free cash flow | — | — | — | — | — | — | 0 | 0 | (4) | (3) | (4) | +113.6% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | (1) | (2) | 3 | 5 | 3 | n/m | |||||
| Net debt | — | — | — | — | — | — | 0 | 1 | (4) | (5) | (3) | n/m | ||||||
| Shareholders’ equity | — | — | — | — | — | — | (1) | (2) | 5 | 6 | 4 | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | — | — | — | 0.00 | (181.11) | (77.32) | (88.51) | (104.32) | (88.5) pt | |||||
| ROIC | — | — | — | — | — | — | 0.00 | 0.00 | (227.03) | (346.52) | (322.91) | (346.5) pt | ||||||
| ROE | — | — | — | — | — | — | 0.00 | 111.27 | (192.96) | (97.99) | (113.96) | (98.0) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | — | — | — | 3 | 4 | 4 | — | +15.5% | |||||
| Revenue/emp, $m | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Kairos Pharma, Ltd. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| PPCB Propanc Biopharma Inc | $1.7M | — (loss-making) | — | — | −99.64% (below 0%: shrinking) | −1,637.42% (below 0%: shrinking) | — | 0.00% | Compare |
| XRTX XORTX Therapeutics Inc. | $1.7M | — (loss-making) | — | — | n/m | −318.40% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| GOVX GeoVax Labs Inc. | $1.6M | — (loss-making) | — (loss-making) | +183.44% (above 0%: growing) | n/m | +15.81% (above 0%: growing) | 100.00% | 0.00% | Compare |
| ITRMF Iterum Therapeutics PLC | $1.6M | — (loss-making) | — (loss-making) | +110.81% (above 0%: growing) | n/m | −179.15% (below 0%: shrinking) | 94.87% | (1,982.31%) | Compare |
| OGEN Oragenics, Inc. | $1.6M | — (loss-making) | — (loss-making) | −75.33% (below 0%: shrinking) | n/m | −66.37% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| VRAX Virax Biolabs Group Limited | $1.6M | — (loss-making) | — (loss-making) | — | −855.56% (below 0%: shrinking) | +32.24% (above 0%: growing) | (53.57%) | 0.00% | Compare |
| KAPA Kairos Pharma, Ltd. | $1.5M | — (loss-making) | — | — | n/m | −25.71% (below 0%: shrinking) | — | 0.00% | |
| CARM Carisma Therapeutics Inc. | $1.5M | — (loss-making) | — (loss-making) | +392.01% (above 0%: growing) | n/m | +114.65% (above 0%: growing) | 100.00% | 96.83% | Compare |
| ABPO Abpro Holdings Inc. | $1.4M | 0.5× | — | — | n/m | −0.48% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| Median of peers | $1.6M | — | — | +147.13% | — | −33.42% | 100.00% | 0.00% |
Pay and ownership Proxy statement filed 22 May 2026
Ownership
Directors and executive officers, together
31.90%
John S. Yu, M.D.
25.00%
Technomedics Management and Systems, Inc.
5.30%
Neil Bhowmick, Ph.D.
5.30%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement